Received 6 July 2004; returned 14 August 2004; revised 6 September 2004; accepted 8 September 2004
|
|
- Helen Jacobs
- 6 years ago
- Views:
Transcription
1 Journal of Antimicrobial Chemotherapy (2004) 54, DOI: /jac/dkh449 Advance Access publication 7 October 2004 Evaluation of the MicroScan ESBL plus confirmation panel for detection of extended-spectrum b-lactamases in clinical isolates of oxyimino-cephalosporin-resistant Gram-negative bacteria Enno Stürenburg 1 *, Melanie Lang 1, Matthias A. Horstkotte 1, Rainer Laufs 1 and Dietrich Mack 1,2 JAC 1 Institut für Infektionsmedizin, Zentrum für Klinisch-Theoretische Medizin, Universitätsklinikum Hamburg- Eppendorf, Martinistrasse 52, D Hamburg, Germany; 2 Chair of Medical Microbiology and Infectious Diseases, Swansea Clinical School, University of Wales Swansea SA2 8PP, UK Received 6 July 2004; returned 14 August 2004; revised 6 September 2004; accepted 8 September 2004 Objective: We aimed to assess the performance of the MicroScan ESBL plus confirmation panel using a series of 87 oxyimino-cephalosporin-resistant Gram-negative bacilli of various species. Methods: Organisms tested included 57 extended-spectrum b-lactamase (ESBL) strains comprising Enterobacter aerogenes (3), Enterobacter cloacae (10), Escherichia coli (11), Klebsiella pneumoniae (26), Klebsiella oxytoca (3) and Proteus mirabilis (4). Also included were 30 strains resistant to oxyimino cephalosporins but lacking ESBLs, which were characterized with other resistance mechanisms, such as inherent clavulanate susceptibility in Acinetobacter spp. (4), hyperproduction of AmpC enzyme in Citrobacter freundii (2), E. aerogenes (3), E. cloacae (3), E. coli (4), Hafnia alvei (1) and Morganella morganii (1), production of plasmid-mediated AmpC b-lactamase in K. pneumoniae (3) and E. coli (3) or hyperproduction of K1 enzyme in K. oxytoca (6). Results: The MicroScan MIC-based clavulanate synergy correctly classified 50 of 57 ESBL strains as ESBL-positive and 23 of 30 non-esbl strains as ESBL-negative (yielding a sensitivity of 88% and a specificity of 76.7%, respectively). False negatives among ESBL producers were highest with Enterobacter spp. due to masking interactions between ESBL and AmpC b-lactamases. False-positive classifications occurred in two Acinetobacter spp., one E. coli producing plasmid-mediated AmpC b-lactamase and two K. oxytoca hyperproducing their chromosomal K1 b-lactamase. Conclusion: The MicroScan clavulanate synergy test proved to be a valuable tool for ESBL confirmation. However, this test has limitations in detecting ESBLs in Enterobacter spp. and in discriminating ESBL-related resistance from the K1 enzyme and from inherent clavulanate susceptibility in Acinetobacter spp. Keywords: ESBLs, ESBL detection, ESBL discrimination, MIC-based clavulanate synergy test Introduction Production of extended-spectrum b-lactamases (ESBLs) has become a major challenge in treating Gram-negative infections. 1,2 Initially these enzymes were limited to Escherichia coli and Klebsiella species and were mainly restricted to certain geographical areas. Since the late 1990s, however, these enzymes have been spreading and ESBLs are reaching other genera, principally Enterobacter and Proteus. 3 6 Besides the growing species diversity, ESBL phenotypes have become more complex due to the production of multiple enzymes, including inhibitor-resistant ESBL variants, dissemination of CTX-M types, plasmid-borne AmpC, production of ESBLs in AmpC-producing strains, enzyme hyperproduction and porin loss The inability to detect such complex resistance phenotypes may have been a major factor in the uncontrolled spread of ESBL-producing organisms and related treatment failures, without any suspicion by the laboratory or physicians of their presence.... *Corresponding author. Tel: ; Fax: ; e.stuerenburg@uke.uni-hamburg.de JAC vol.54 no.5 q The British Society for Antimicrobial Chemotherapy 2004; all rights reserved.
2 ESBL detection by MicroScan ESBL plus panel Unfortunately, current diagnostic means failed to keep pace with changing conditions. The NCCLS has issued guidelines for phenotypic confirmation of suspected ESBL strains among E. coli, Klebsiella oxytoca and Klebsiella pneumoniae, but there are currently no interpretative criteria available for other genera, or the methods to be applied for ESBL detection against the background of coexisting resistance mechanisms. 16 The NCCLS recommendation still relies on the MIC difference test, in which a b-lactamase inhibitor is used to protect the activity of an indicator drug against an ESBL-producing strain. This test is considered positive when the suspected organism exhibits a lowering of >_3 two-fold dilution steps in its MICs of ceftazidime or cefotaxime in the presence of a fixed concentration (4 mg/l) of clavulanic acid, versus its MIC when tested alone. 16 For daily routine, this protocol has been translated into several customized microtitre formats, the MicroScan ESBL plus panel (Dade Behring) being a newer one among them. Its advantage is that it can be processed in a fully automated fashion, by using the Walkaway 96 SI instrument (Dade Behring, Schwalbach, Germany). In this study, we aimed to determine whether the MicroScan ESBL plus panel would be able to discriminate between ESBLs, AmpC b-lactamases, high levels of K1 b-lactamase and inherent clavulanate susceptibility in isolates of Acinetobacter spp., Enterobacter aerogenes, Enterobacter cloacae, E. coli, Hafnia alvei, K. oxytoca, K. pneumoniae and Morganella morganii. Some of these strains had been used in previous studies of commercially available Etest strips and microdilution panels. 17,18 Molecular procedures including PCR and nucleotide sequencing were used as the reference method. Materials and methods Bacterial strains The bacterial strains selected for this study included 87 oxyiminocephalosporin-resistant isolates of Gram-negative bacteria, the majority of which have been characterized previously. 17,18 The remaining strains were recent isolates gathered from patients attending the university hospital Hamburg-Eppendorf, Germany, affiliated with our institution. Species identification was performed by routine laboratory methods, such as the API32E (biomérieux, Marcy l Étoile, France). PCR of b-lactamase-encoding genes Reference confirmation for ESBL production was by molecular characterization, i.e. by PCR analysis for b-lactamase genes of the families CTX-M, SHV, TEM, OXA, VEB and PER and where applicable by nucleotide sequencing. The primers used to amplify the targeted genes were: TEM-F, 5 0 -TCCGCTCATGAGACAAT- AACC-3 0 and TEM-R, 5 0 -TTGGTCTGACAGTTACCAATGC-3 0 ; SHV-F, 5 0 -TTATCTCCCTGTTAGCCACC-3 0 and SHV-R, 5 0 -GAT- TTGCTGATTTCGCTCGG-3 0 ; 19 CTX-M-F, 5 0 -TCTTCCAGAATA- AGGAATCCC-3 0 and CTX-M-R, 5 0 -CCGTTTCCGCTATTAC- AAAC-3 0 ; OXA-1F, 5 0 -ACACAATACATATCAACTTCGC-3 0 and OXA-1R, 5 0 -AGTGTGTTTAGAATGGTGATC-3 0 ; 20 OXA-2F, 5 0 -TTCAAGCCAAAGGCACGATAG-3 0 and OXA-2R, 5 0 -TCCGA- GTTGACTGCCGGGTTG-3 0 ; 20 OXA-10F, 5 0 -CGTGCTTTGTAAA- AGTAGCAG-3 0 and OXA-10R, 5 0 -CATGATTTTGGTGGGA- ATGG-3 0 ; 20 VEB-1F, 5 0 -CGACTTCCATTTCCCGATGC-3 0 and VEB-1R, 5 0 -GGACTCTGCAACAAATACGC-3 0 ; 21 PER-F, 5 0 -ATG- AATGTCATTATAAAAGC-3 0 and PER-R, 5 0 -AATTTGGGCTTA- GGGCAGAA The nucleotide sequences were determined by bidirectional sequencing of PCR products, carried out by the Big- Dye dideoxy chain termination method on an ABI Prism 310 DNA sequencer (Perkin-Elmer Corp., Foster City, CA, USA). The nucleotide sequences were analysed using commercial software (Vector NTI suite; InforMax Inc.) against the GenBank database. ESBL-positive strains Sensitivity was calculated with 57 ESBL-positive strains, which included 40 bacteria (E. coli, K. oxytoca and K. pneumoniae) targeted by the NCCLS MIC difference test and 17 non-target bacteria, such as E. aerogenes, E. cloacae and Proteus mirabilis. In detail, the clinical isolates consisted of E. aerogenes (n = 3), E. cloacae (n = 10), E. coli (n = 11), K. oxytoca (n = 3), K. pneumoniae (n = 26) and P. mirabilis (n = 4). The E. aerogenes strains analysed harboured CTX-M-1 (n = 2) and SHV-5 (n = 1) ESBLs. The isolates of E. cloacae included SHV-12 (n = 3) and TEM-type (ABL: A184V) (n = 7) ESBLs. The E. coli strains included SHV-2 (n = 2), SHV-5 (n = 1), SHV-12 (n = 3), TEM-26 (n = 1), TEM-52 (n = 1), TEM-111 (n = 1), CTX-M-1 (n = 1) and CTX-M-23 (n = 1). 22 The K. oxytoca isolates harboured CTX-M-1 (n = 2) and SHV-12 (n = 1). The K. pneumoniae strains harboured SHV-2 (n = 5), SHV-2a (n = 1), SHV-5 (n = 4), SHV-12 (n = 11), SHV-18 (n = 1), SHV-19 (n = 1), LEN-type (ABL: N53S, A201P, P218A) (n = 1), TEM-47 (n = 1) and TEM-110 (n = 1). The P. mirabilis strains included CTX-M-1 (n = 1), CTX-M-15 (n = 1), CTX-M-22 (n = 1) and TEM-92 (n = 1). ESBL-negative strains Specificity was calculated with 30 clinical strains resistant to oxyimino cephalosporins that failed to produce any ESBLs according to the PCR-based technique. Rather, in these strains, the likely type of b-lactamase present was inferred on the basis of the overall susceptibility profile. 23,24 The following patterns were used for phenotypic detection of (i) hyperproduction of AmpC chromosomal b-lactamase (AmpC high): resistant to ureidopenicillins and to cephalosporins in the oxyimino group (cefotaxime, cefotaxime/clavulanate, ceftazidime, ceftazidime/clavulanate and cefpodoxime) and the 7-amethoxy group (cefoxitin and cefotetan). 23 (ii) Within the AmpC high group, there were E. coli and K. pneumoniae strains that produced a plasmid-mediated AmpC b-lactamase, as detected by a multiplex PCR assay for detection of plasmid-mediated ampc b-lactamase genes (plasmid AmpC). 8,25 (iii) Hyperproduction of K. oxytoca chromosomal K1 b-lactamase (K1 high): resistant to ureidopenicillins, resistant to cefuroxime and aztreonam, and resistant or intermediate to cefotaxime and ceftriaxone, but susceptible to ceftazidime. 23 By these criteria, the non-esbl strains consisted of four strains of Acinetobacter spp. (interpretative reading not applicable); two strains of Citrobacter freundii (likely mechanism of resistance: AmpC high); three strains of E. aerogenes (AmpC high); three strains of E. cloacae (AmpC high); three strains of E. coli (plasmid AmpC, multiplex PCR: CIT-type); four strains of E. coli (AmpC high), one strain of H. alvei (AmpC high); six strains of K. oxytoca isolates (K1 high); three strains of K. pneumoniae (plasmid AmpC, multiplex PCR: CIT-type); one strain of M. morganii (AmpC high). Panel processing and interpretation Antibiotic susceptibilities were determined by overnight microdilution, with commercial dehydrated panels provided by Dade Behring. The ESBL plus panels were prepared and inoculated according to the manufacturer s recommended procedures. 871
3 E. Stürenburg et al. The inoculated panels were then placed into the Walkaway 96 SI instrument (Dade Behring) for incubation, final reading and interpretation of the results, which was conducted according to NCCLS criteria. 16 The following antimicrobial agents (concentration ranges in mg/l) were used in the MicroScan ESBL plus panel: aztreonam, ; cefepime, 1 32; cefotetan, 1 32; cefpodoxime, ; cefotaxime, ; cefotaxime/clavulanate, 0.125/4 16/4; cefoxitin, 2 32; ceftazidime, ; ceftazidime/clavulanate, 0.125/4 16/4; ceftriaxone, 1 64; imipenem, ; meropenem, ; piperacillin, Data analysis For isolates for which ceftazidime or cefotaxime MICs were >128 mg/l, the MIC was taken as 256 mg/l and the reduction in the ceftazidime (cefotaxime) MIC was calculated from that value. Strains for which the results between the methods were discordant were tested again, and only concordant and reproducible data were analysed. Results A total of 87 strains of Gram-negative bacilli resistant to oxyimino cephalosporins were chosen for the study. Fifty-seven (57) strains were shown by PCR and nucleotide sequencing to contain at least one of the genes bla TEM, bla SHV and bla CTX-M, confirming the ESBL status (Table 1). Thirty additional strains were characterized with other resistance mechanisms, such as inherent susceptibility to clavulanate (four strains of Acinetobacter spp.), hyperproduction of AmpC chromosomal b-lactamase (two strains of C. freundii, three strains of E. aerogenes, three strains of E. cloacae, four strains of E. coli, one strain of H. alvei, one strain of M. morganii), production of plasmid-mediated AmpC b-lactamase (three strains of K. pneumoniae, three strains of E. coli) or hyperproduction of K1 chromosomal b-lactamase (six strains of K. oxytoca) (Table 1). As an indicator for ESBL screening, the susceptibilities of the organisms to the five extended-spectrum b-lactams available on the MicroScan ESBL plus panel were as follows: cefotaxime (98%), cefpodoxime (98%), ceftriaxone (100%), aztreonam (94%) and ceftazidime (96%) when interpreted using the NCCLS criteria. 16 Leaving aside ceftriaxone, these data add support to the NCCLS recommendation that 100% sensitivity of ESBL screening can only be achieved by testing more than one agent. 16 Importantly, no single drug at any one concentration accurately differentiated between strains producing ESBL and non-esbl phenotypes (data not shown). The majority of Table 1. MicroScan MIC difference test results using the ESBL plus confirmation panel CTX/CLA MIC difference test CAZ/CLA MIC difference test Status positive log 2 reduction in MIC log 2 reduction in MIC mean range negative/ ND+ d positive mean range negative/ ND+ d ESBL organisms (n = 57) ( ) ( ) 11 E. aerogenes (n = 3) (5.0) 1 e 3 E. cloacae (n = 10) ( ) ( ) 6 E. coli (n = 11) ( ) ( ) K. oxytoca (n = 3) ( ) ( ) K. pneumoniae (n = 26) a ( ) ( ) P. mirabilis (n = 4) ( ) ( ) 2 ESBL types (n = 58) a TEM (n = 12) ( ) ( ) 6 SHV (n = 36) ( ) ( ) 1 CTX-M (n = 10) ( ) ( ) 4 Non-ESBL strains (n = 30) Acinetobacter spp. (n = 4) ( ) ( ) 2 C. freundii AmpC high (n =2) 2 2 E. aerogenes AmpC high (n =3) 3 3 E. cloacae AmpC high (n =3) 3 3 E. coli AmpC high (n =4) 4 4 E. coli plasmid AmpC (n =3) b,c ( ) ( ) H. alvei AmpC high (n =1) 1 1 K. oxytoca K1 high (n = 6) ( ) 4 6 K. pneumoniae plasmid AmpC (n =3) b 3 3 M. morganii AmpC high (n =1) 1 1 CTX, cefotaxime; CLA, clavulanic acid; CAZ, ceftazidime. a One strain of K. pneumoniae produced two ESBL enzymes. b Plasmid derivates of AmpC b-lactamase included CIT-type enzymes (origin C. freundii). c Two strains of E. coli produced both a plasmid-mediated AmpC b-lactamase and an ESBL d When MIC values were above the test device range, interpretation was non-determinable, ND+. e The dash ( ) sign denotes that no strains were detected. 872
4 ESBL detection by MicroScan ESBL plus panel Figure 1. Plot showing the frequency of the MIC reductions (two-fold dilution steps) for ESBL producers as a whole (circles, n = 57) and for the subset of CTX-M producers (triangles, n = 10) and ESBL-producing Enterobacter strains (squares, n = 13), obtained with the clavulanate synergy test using cefotaxime (CTX) and ceftazidime (CAZ). Negative values in MIC reduction are due to the ability of clavulanic acid to induce the chromosomal AmpC b-lactamase, resulting in MICs of the combinations higher than that of the drug alone. The dashed line represents the current MIC breakpoint for ESBL confirmation (i.e. a lowering of >_ 3 two-fold dilutions in the MIC of either ceftazidime or cefotaxime by clavulanic acid), as recommended by the NCCLS. non-esbl phenotypes would be considered ESBL producers by these criteria, but very few would be confirmed as such by the confirmatory tests (as described below). If a lowering of >_3 two-fold dilutions in the MIC of either ceftazidime or cefotaxime was taken as the criterion for ESBL confirmation, the MIC difference test was able to detect 50 ESBL strains out of the total of 57 identified by molecular characterization (yielding 88% sensitivity). False negatives among ESBL producers were highest in tests with Enterobacter spp. (Table 1 and Figure 1). Addition of clavulanic acid to ceftazidime (or cefotaxime) failed to lower MICs at least eight-fold in tests with nine (or seven) out of 13 ESBL-producing Enterobacter strains. This poor performance was partly due to the ability of clavulanate to induce the chromosomal AmpC b-lactamase, which often resulted in MICs of the combinations higher than that of the drug alone (Table 1 and Figure 1). The remaining ESBL-producing isolates demonstrated a significant clavulanic acid effect with both cefotaxime and ceftazidime (Table 1 and Figure 1). Only in tests with the CTX-M producers was cefotaxime clearly the single best antibiotic in its ability to confirm ESBL status, since clavulanate synergy was much more pronounced with cefotaxime (mean log 2 reduction in MIC, 8.7) than with ceftazidime (mean log 2 reduction in MIC, 4.8). In fact, when used alone, MIC difference testing with ceftazidime would have failed to recognize four out of 10 CTX-Mproducing ESBL strains (Table 1 and Figure 1). Among the 30 isolates resistant to oxyimino cephalosporins but lacking ESBLs, we observed apparently positive results in MIC difference testing (three- to eight-fold increase in the MIC) with cefotaxime and ceftazidime in seven and five cases, respectively (Table 1 and Figure 2). Since the NCCLS requires only one of the ESBL tests to be positive for an organism to confirm ESBL production, this resulted in an overall specificity of only 76.7% (23/30 strains). Misidentification occurred in Acinetobacter spp. Figure 2. Plot showing the frequency of the MIC reductions (two-fold dilution steps) for non-esbl resistance phenotypes (circles: hyperproduction of AmpC chromosomal b-lactamase; triangles: hyperproduction of K1 chromosomal b-lactamase; squares: plasmid-mediated AmpC b-lactamase; diamonds: Acinetobacter spp.), obtained with the clavulanate synergy test using cefotaxime (CTX) and ceftazidime (CAZ). The dashed line represents the current MIC breakpoint for ESBL confirmation (i.e. a lowering of >_3 two-fold dilutions in the MIC of either ceftazidime or cefotaxime by clavulanic acid), as recommended by the NCCLS. (two strains), E. coli producing plasmid-mediated AmpC b-lactamase (three strains) and K. oxytoca hyperproducing their chromosomal K1 b-lactamase (two strains). An effect of clavulanic acid on the activities of both cefotaxime and ceftazidime was noted in Acinetobacter spp. and E. coli producing plasmidmediated AmpC enzymes, whereas in K. oxytoca hyperproducing K1 enzyme only cefotaxime was affected (Table 1 and Figure 2). With strains giving inconsistent results, both molecular characterization and susceptibility tests were repeated. On retesting, two E. coli were detected to have both a plasmid-mediated AmpC b-lactamase and an ESBL (CIT-type enzyme plus CTX-M-15; CIT-type enzyme plus CTX-M-33). Coexistence of AmpC and ESBL, however, does not provide a full explanation, since responsiveness to clavulanate remained unexplained in one repeatedly ESBL-negative E. coli strain. Even so, excluding the two E. coli strains producing both an ESBL and an AmpC enzyme from the calculation enhanced specificity to 82.1% (23/28 strains). Discussion The NCCLS has issued recommendations for the screening and confirmation of ESBLs in isolates of E. coli and Klebsiella spp. using broth microdilution methods. 16,26 The MicroScan product line offers a fully automated procedure adapting the NCCLS recommendation to confirm ESBL production in suspected strains. However, as b-lactamases are becoming more and more complex, several practical problems emerge in terms of following the NCCLS recommendations. In our study, we have evaluated the MicroScan procedure with regard to its discriminatory potential between ESBL production and other non-esblassociated mechanisms of resistance to extended-spectrum cephalosporins in various Gram-negative bacteria. One issue is that the presence of ESBLs can be masked by the expression of AmpC b-lactamases, which can be generated 873
5 E. Stürenburg et al. by chromosomal (e.g. in most Enterobacter spp., Serratia spp., C. freundii, M. morganii, Providentia spp. and Pseudomonas aeruginosa) or plasmid genes (mostly in E. coli and Klebsiella spp.). Plasmid-mediated AmpC b-lactamases are thought to have originated from the chromosomes of the former Enterobacteriaceae species. 27 Regardless of background, AmpC enzyme can interfere with clavulanate synergy tests. 28,29 With the chromosomal type of enzyme, clavulanic acid may act as an inducer of high-level production, and may then attack the indicator cephalosporin, thus masking any synergy arising from a coexisting ESBL. 28,29 Accordingly, in the present study, clavulanatebased synergy testing failed to detect reliably ESBL production in tests with 54% 69% ESBL-producing Enterobacter strains. The overall ability of clavulanic acid to lower the MICs of either cefotaxime or ceftazidime, due to these constraints, was diminished to 50/57 strains (88% sensitivity) and 46/57 strains (81% sensitivity), respectively. Even though they are not inducible, plasmid-encoded AmpC b-lactamases typically are expressed at medium to high levels. Like their counterpart on the chromosome, plasmid-encoded AmpC b-lactamases provide a broader spectrum of resistance than ESBL and are not blocked by commercially available inhibitors. 8,27 Thus, high-level expression of a plasmid-mediated AmpC enzyme may also prevent recognition of an ESBL. In our study, two E. coli strains produced both a CTX-M b-lactamase and a CIT-type plasmid-mediated AmpC b-lactamase. In preliminary studies with these strains, dominant AmpC production covered and masked underlying ESBL production. Thus, these strains were initially considered only in the AmpC group until retesting was performed and the ESBL content was detected. Approaches to overcome these difficulties include the use of tazobactam or sulbactam, which are much less likely to induce AmpC b-lactamases and are therefore preferable inhibitors for ESBL detection tests with these organisms, or testing cefepime as an ESBL detection agent. 28 Cefepime is a more reliable detection agent for ESBLs in the presence of an AmpC b-lactamase, as this drug is stable to AmpC b-lactamases, but labile to ESBLs. 28 In a previous study employing the Etest ESBL, cefepime with and without clavulanic acid had promising utility in identifying ESBLs in isolates that also contained an AmpC b-lactamase. 18 Another issue of vital importance is which indicator cephalosporin should be tested. Synergy testing may fail to identify CTX-M positive isolates as ESBL producers if ceftazidime is used as the sole detection agent (as seen in the subset analysis of the CTX-M producers tested in this study). Relying on cefotaxime alone, on the other hand, is unreliable in distinguishing ESBL producers from hyperproducers of the K1 enzyme in K. oxytoca. As shown previously with the ESBL Etest and (as here) with a microdilution technique, many of the cefotaxime synergy-positive K. oxytoca isolates are hyperproducers of their chromosomal K1 b-lactamase and are lacking an ESBL. 17,18,30 Which bacteria should be excluded from routine ESBL testing has not received much attention. In the present study, we have tested six Acinetobacter strains. We observed ostensibly positive results with cefotaxime and ceftazidime in two out of six strains, although PCR analysis showed that these strains were lacking an ESBL. These results confirmed the suspicion that Acinetobacters often give apparently positive results, due to their susceptibility of the inhibitors themselves, and thus should not be tested for ESBL production by inhibitor-based methods. A similar difficulty exists with Stenotrophomonas, where clavulanate synergy tests can produce false-positive results via inhibition of the L2 chromosomal b-lactamase. 34 Given that ESBLs are spreading and are reaching non-fermenters as well, principally Acinetobacter, these particularities could become clinically important in the future. Overall, this study demonstrated that the MicroScan MIC difference test, using both ceftazidime and cefotaxime, is a sensitive tool in its ability to confirm the ESBL status of a given Gram-negative isolate. However, as with other techniques, its constraints must be recognized. First, and most importantly, clavulante synergy can give false-negative results in an AmpC environment, whether chromosomal or plasmid-encoded. Secondly, false-positive ESBL results can occur, due to the presence of other clavulanate-responsive b-lactamases, mainly the K1 b-lactamase of K. oxytoca, or due to clavulanate susceptibility, which is inherent to the species, as for Acinetobacter spp. As ESBL phenotypes become more and more complex, emphasis on an upgrade of the NCCLS recommendations seems to be warranted. Acknowledgements We thank Djahesh Noor for excellent technical assistance on this project and Brigitta Pölkner, Jana Lauterberg, Bärbel Erichsen and Kerstin Wagner (all Dade Behring) for making this study possible. We are grateful to the following for sharing their ESBL strains with us for this research project: Mrs Aline Wenger, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland (10 E. cloacae isolates); Dr Elke Halle, Institut für Mikrobiologie und Hygiene, Campus Charité Mitte, Berlin, Germany (one P. mirabilis strain); Dr Karin Schwegmann, Niedersächsisches Landesgesundheitsamt, Hannover, Germany (one P. mirabilis strain). This study was supported by Dade Behring. References 1. Stürenburg, E. & Mack, D. (2003). Extended-spectrum b-lactamases: implications for the clinical microbiology laboratory. Journal of Infection 47, Bradford, P. A. (2001). Extended-spectrum b-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clinical Microbiology Reviews 14, Albertini, M. T., Benoit, C., Berardi, L. et al. (2002). Surveillance of methicillin-resistant Staphylococcus aureus (MRSA) and Enterobacteriaceae producing extended-spectrum b-lactamase (ESBLE) in Northern France: a five-year multicentre incidence study. Journal of Hospital Infection 52, Spanu, T., Luzzaro, F., Perilli, M. et al. (2002). Occurrence of extended-spectrum b-lactamases in members of the family Enterobacteriaceae in Italy: implications for resistance to b-lactams and other antimicrobial drugs. Antimicrobial Agents and Chemotherapy 46, Coudron, P. E., Moland, E. S. & Sanders, C. C. (1997). Occurrence and detection of extended-spectrum b-lactamases in members of the family Enterobacteriaceae at a veterans medical center: seek and you may find. Journal of Clinical Microbiology 35, Bonnet, R., De Champs, C., Sirot, D. et al. (1999). Diversity of TEM mutants in Proteus mirabilis. Antimicrobial Agents and Chemotherapy 43,
6 ESBL detection by MicroScan ESBL plus panel 7. Bonomo, R. A. & Rice, L. B. (1999). Inhibitor resistant class A b-lactamases. Frontiers in Bioscience 4, e34 e Philippon, A., Arlet, G. & Jacoby, G. A. (2002). Plasmiddetermined AmpC-type b-lactamases. Antimicrobial Agents and Chemotherapy 46, Xiang, X., Shannon, K. & French, G. (1997). Mechanism and stability of hyperproduction of the extended-spectrum b-lactamase SHV-5 in Klebsiella pneumoniae. Journal of Antimicrobial Chemotherapy 40, Martinez-Martinez, L., Pascual, A., Hernandez-Alles, S. et al. (1999). Roles of b-lactamases and porins in activities of carbapenems and cephalosporins against Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy 43, Gazouli, M., Tzouvelekis, L. S., Prinarakis, E. E. et al. (1996). Transferable cefoxitin resistance in enterobacteria from Greek hospitals and characterization of a plasmid-mediated group 1 b-lactamase (LAT-2). Antimicrobial Agents and Chemotherapy 40, Gazouli, M., Tzouvelekis, L. S., Vatopoulos, A. C. et al. (1998). Transferable class C b-lactamases in Escherichia coli strains isolated in Greek hospitals and characterization of two enzyme variants (LAT-3 and LAT-4) closely related to Citrobacter freundii AmpC b-lactamase. Journal of Antimicrobial Chemotherapy 42, M Zali, F. H., Heritage, J., Gascoyne-Binzi, D. M. et al. (1997). Transcontinental importation into the UK of Escherichia coli expressing a plasmid-mediated AmpC-type b-lactamase exposed during an outbreak of SHV-5 extended-spectrum b-lactamase in a Leeds hospital. Journal of Antimicrobial Chemotherapy 40, Stürenburg, E., Sobottka, I., Mack, D. et al. (2002). Cloning and sequencing of Enterobacter aerogenes OmpC-type osmoporin linked to carbapenem resistance. International Journal of Medical Microbiology 291, Bonnet, R. (2004). Growing group of extended-spectrum b-lactamases: the CTX-M enzymes. Antimicrobial Agents and Chemotherapy 48, National Committee for Clinical Laboratory Standards. (2003). Performance Standards for Antimicrobial Susceptibility Testing Thirteenth Informational Supplement M100-S13. NCCLS, Wayne, PA, USA. 17. Stürenburg, E., Sobottka, I., Feucht, H. H. et al. (2003). Comparison of BDPhoenix and VITEK2 automated antimicrobial susceptibility test systems for extended-spectrum b-lactamase detection in Escherichia coli and Klebsiella species clinical isolates. Diagnostic Microbiology and Infectious Disease 45, Stürenburg, E., Sobottka, I., Noor, D. et al. (2004). Evaluation of a new cefepime-clavulanate ESBL Etest to detect extended-spectrum b-lactamases in an Enterobacteriaceae strain collection. Journal of Antimicrobial Chemotherapy 54, Arlet, G., Rouveau, M. & Philippon, A. (1997). Substitution of alanine for aspartate at position 179 in the SHV-6 extended-spectrum b-lactamase. FEMS Microbiology Letters 152, Steward, C. D., Rasheed, J. K., Hubert, S. K. et al. (2001). Characterization of clinical isolates of Klebsiella pneumoniae from 19 laboratories using the National Committee for Clinical Laboratory Standards extended-spectrum b-lactamase detection methods. Journal of Clinical Microbiology 39, Poirel, L., Le Thomas, I., Naas, T. et al. (2000). Biochemical sequence analyses of GES-1, a novel class A extended-spectrum b-lactamase, and the class 1 integron In52 from Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy 44, Stürenburg, E., Kühn, A., Mack, D. et al. (2004). A novel extended-spectrum b-lactamase CTX-M-23 with a P167T substitution in the active-site omega loop associated with ceftazidime resistance. Journal of Antimicrobial Chemotherapy 54, Livermore, D. M. (1995). b -Lactamases in laboratory and clinical resistance. Clinical Microbiology Reviews 8, Livermore, D. M., Winstanley, T. G. & Shannon, K. P. (2001). Interpretative reading: recognizing the unusual and inferring resistance mechanisms from resistance phenotypes. Journal of Antimicrobial Chemotherapy 48, Perez-Perez, F. J. & Hanson, N. D. (2002). Detection of plasmid-mediated AmpC b-lactamase genes in clinical isolates by using multiplex PCR. Journal of Clinical Microbiology 40, National Committee for Clinical Laboratory Standards. (2003). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically Sixth Edition: Approved Standard M7-A6. Wayne, PA, USA. 27. Hanson, N. D. (2003). AmpC b-lactamases: what do we need to know for the future? Journal of Antimicrobial Chemotherapy 52, Thomson, K. S. (2001). Controversies about extended-spectrum and AmpC b-lactamases. Emerging Infectious Diseases 7, Livermore, D. M. & Brown, D. F. (2001). Detection of b-lactamase-mediated resistance. Journal of Antimicrobial Chemotherapy 48,Suppl 1, Potz, N. A., Colman, M., Warner, M. et al. (2004). False-positive extended-spectrum b-lactamase tests for Klebsiella oxytoca strains hyperproducing K1 b-lactamase. Journal of Antimicrobial Chemotherapy 53, Urban, C., Go, E., Mariano, N. et al. (1995). Interaction of sulbactam, clavulanic acid and tazobactam with penicillinbinding proteins of imipenem-resistant and -susceptible Acinetobacter baumannii. FEMS Microbiology Letters 125, Higgins, P. G., Wisplinghoff, H., Stefanik, D. et al. (2004). In vitro activities of the b-lactamase inhibitors clavulanic acid, sulbactam, and tazobactam alone or in combination with b-lactams against epidemiologically characterized multidrug-resistant Acinetobacter baumannii strains. Antimicrobial Agents and Chemotherapy 48, Pandey, A., Kapil, A., Sood, S. et al. (1998). In vitro activities of ampicillin-sulbactam and amoxicillin-clavulanic acid against Acinetobacter baumannii. Journal of Clinical Microbiology 36, Walsh, T. R., MacGowan, A. P. & Bennett, P. M. (1997). Sequence analysis and enzyme kinetics of the L2 serine b-lactamase from Stenotrophomonas maltophilia. Antimicrobial Agents and Chemotherapy 41, Poirel, L., Karim, A., Mercat, A. et al. (1999). Extended-spectrum b-lactamase-producing strain of Acinetobacter baumannii isolated from a patient in France. Journal of Antimicrobial Chemotherapy 43, Vahaboglu, H., Ozturk, R., Aygun, H. et al. (1997). Widespread detection of PER-1-type extended-spectrum b-lactamases among nosocomial Acinetobacter and Pseudomonas aeruginosa isolates in Turkey: a nationwide multicenter study. Antimicrobial Agents and Chemotherapy 41, Nordmann, P. (1998). Trends in b-lactam resistance among Enterobacteriaceae. Clinical Infectious Diseases 27, S
Prevalence and molecular characterization of clinical isolates of Escherichia coli expressing an AmpC phenotype
J Antimicrob Chemother 2010; 65: 460 464 doi:10.1093/jac/dkp484 Advance publication 22 January 2010 Prevalence and molecular characterization of clinical isolates of Escherichia coli expressing an AmpC
More informationJOHN DEMPSEY HOSPITAL Farmington, Connecticut ANTIBIOTIC SUSCEPTIBILITY PROFILES for INPATIENT Bacterial Isolates
JOHN DEMPSEY HOSPITAL Farmington, Connecticut 2017 ANTIBIOTIC SUSCEPTIBILITY PROFILES for INPATIENT Bacterial Isolates **GROUPED BY CULTURE SOURCES** (data from 1/1/17 1/1/18) Prepared by: UCHC/JDH Antimicrobial
More informationSUMMARY. Key words: antibioticresistance, Enterobacteriaceae, ESBL, CTX-M,
SUMMARY Key words: antibioticresistance, Enterobacteriaceae, ESBL, CTX-M, The doctoral thesis entitled Prevalence of Enterobacteriaceae producing extendedspectrum beta-lactamases (ESBL) isolated from broilers
More informationDetection of Extended-Spectrum Beta-Lactamases among Enterobacteriaceae by Use of Semiautomated Microbiology Systems and Manual Detection Procedures
JOURNAL OF CLINICAL MICROBIOLOGY, Apr. 2007, p. 1167 1174 Vol. 45, No. 4 0095-1137/07/$08.00 0 doi:10.1128/jcm.01988-06 Copyright 2007, American Society for Microbiology. All Rights Reserved. of Extended-Spectrum
More informationCharacterization of Clinical Isolates of Enterobacteriaceae from Italy by the BD Phoenix Extended-Spectrum -Lactamase Detection Method
JOURNAL OF CLINICAL MICROBIOLOGY, Apr. 2003, p. 1463 1468 Vol. 41, No. 4 0095-1137/03/$08.00 0 DOI: 10.1128/JCM.41.4.1463 1468.2003 Copyright 2003, American Society for Microbiology. All Rights Reserved.
More informationUse of Molecular Assays for Resistance Detection
Use of Molecular Assays for Resistance Detection Antimicrobial resistance and susceptibility are complex, and current in vitro methods have been developed to predict a microorganism s response to antibacterial
More informationThe biomérieux solution. VITEK2 : A challenge with ESBL ESBL. Karen Bush
International Newsletter n 4 December 2003 Through the IDENTIFYING RESISTANCE Newsletter, biomérieux s ambition is to contribute to the awareness and progress in the field of resistance to antibiotics.
More informationH. Wu, B.-G. Liu, J.-H. Liu, Y.-S. Pan, L. Yuan and G.-Z. Hu
Phenotypic and molecular characterization of CTX-M-14 extended-spectrum β-lactamase and plasmid-mediated ACT-like AmpC β-lactamase produced by Klebsiella pneumoniae isolates from chickens in Henan Province,
More informationWELCOME. to the CDS WORKSHOP
WELCOME to the CDS WORKSHOP Sydney 2010 Excel Spreadsheet for Registration Recent Additions to the CDS Doripenem 10mg disc A carbapenem claimed to be more active against Pseudomonas than Meropenem Daptomycin:
More informationCME/SAM. Clinical Laboratory Detection of AmpC β-lactamase Does It Affect Patient Outcome?
Microbiology and Infectious Disease / Laboratory Detection of AmpC β-lactamase Clinical Laboratory Detection of AmpC β-lactamase Does It Affect Patient Outcome? Kenneth H. Rand, MD, 1 Bradley Turner, MD,
More informationINTRODUCTION METHODS Printed in Great Britain. Correspondence Mark A. Fisher
Journal of Medical Microbiology (2009), 58, 774 778 DOI 10.1099/jmm.0.006171-0 Performance of the Phoenix bacterial identification system compared with disc diffusion methods for identifying extended-spectrum
More informationExtended Spectrum β-lactamases: Critical Tools of Bacterial Resistance
Review Article Mahidol University Journal of Pharmaceutical Science 2012; 39 (1), 1-8 Extended Spectrum β-lactamases: Critical Tools of Bacterial Resistance Department of Microbiology, Faculty of Pharmacy,
More informationExtended-spectrum b-lactamases of Escherichia coli and Klebsiella pneumoniae screened by the VITEK 2 system
Journal of Medical Microbiology (2011), 60, 756 760 DOI 10.1099/jmm.0.024075-0 Extended-spectrum b-lactamases of Escherichia coli and Klebsiella pneumoniae screened by the VITEK 2 system Maria José Espinar,
More informationExtended-Spectrum -Lactamases in the 21st Century: Characterization, Epidemiology, and Detection of This Important Resistance Threat
CLINICAL MICROBIOLOGY REVIEWS, Oct. 2001, p. 933 951 Vol. 14, No. 4 0893-8512/01/$04.00 0 DOI: 10.1128/CMR.14.4.933 951.2001 Copyright 2001, American Society for Microbiology. All Rights Reserved. Extended-Spectrum
More informationCRE Laboratory Testing and CRE Lab Testing Recommendations in-depth recommendations on CRE laboratory detection
December 2014 Dear Laboratory Director, The Illinois Department of Public Health (IDPH) amended the Control of Communicable Diseases Code (77 Ill. Adm. Code 690) to require reporting of Carbapenem-Resistant
More informationBeta-lactamase inhibition: A potted history of beta lactamase and lessons from recent development of betalactamase inhibiter combinations
Beta-lactamase inhibition: A potted history of beta lactamase and lessons from recent development of betalactamase inhibiter combinations Dr Shampa Das, Senior Lecturer, Molecular and Clinical Pharmacology,
More informationResistance, Yonsei University College of Medicine, Seoul, Korea; and 2 Department of
AAC Accepts, published online ahead of print on March 0 Antimicrob. Agents Chemother. doi:./aac.0- Copyright 0, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.
More informationEvaluation of the NCCLS Extended-Spectrum -Lactamase Confirmation Methods for Escherichia coli with Isolates Collected during Project ICARE
JOURNAL OF CLINICAL MICROBIOLOGY, July 2003, p. 3142 3146 Vol. 41, No. 7 0095-1137/03/$08.00 0 DOI: 10.1128/JCM.41.7.3142 3146.2003 Copyright 2003, American Society for Microbiology. All Rights Reserved.
More informationEvaluation of the NCCLS Extended-Spectrum -Lactamase Confirmation Methods for Escherichia coli with Isolates Collected during Project ICARE
JOURNAL OF CLINICAL MICROBIOLOGY, July 2003, p. 3142 3146 Vol. 41, No. 7 0095-1137/03/$08.00 0 DOI: 10.1128/JCM.41.7.3142 3146.2003 Copyright 2003, American Society for Microbiology. All Rights Reserved.
More informationAre There Non-Carbapenem β-lactam Options for Treating ESBL Infections?
CIDEIM Are There Non-Carbapenem β-lactam Options for Treating ESBL Infections? Pranita D. Tamma, M.D., M.H.S. Assistant Professor, Pediatrics Director, Pediatric Antimicrobial Stewardship Program CIDEIM
More informationReceived 16 September 2005/Accepted 20 September 2005
JOURNAL OF CLINICAL MICROBIOLOGY, Dec. 2005, p. 5945 5949 Vol. 43, No. 12 0095-1137/05/$08.00 0 doi:10.1128/jcm.43.12.5945 5949.2005 Copyright 2005, American Society for Microbiology. All Rights Reserved.
More informationExtended double disc synergy testing reveals a low prevalence of extended-spectrum b-lactamases in Enterobacter spp. in Vienna, Austria
Journal of Antimicrobial Chemotherapy (2007) 59, 854 859 doi:10.1093/jac/dkm060 Advance Access publication 8 March 2007 Extended double disc synergy testing reveals a low prevalence of extended-spectrum
More informationAdvances in Life Science and Technology ISSN (Paper) ISSN X (Online) Vol.13, 2013
The Reliability of Using Vitek 2 Compact System to Detect Extended-Spectrum Beta-lactamase-producing Isolates in Escherichia coli and Klebsiella pneumoniae in Accra, Ghana *Henry Kwadwo Hackman 1, George
More informationEvaluation of a Double Synergy Differential Test (DSDT) for differential detection of ESBL and AmpC-type
NEW MICROBIOLOGICA, 35, 221-225, 2012 Evaluation of a Double Synergy Differential Test (DSDT) for differential detection of ESBL and AmpC-type β-lactamases in Escherichia coli, Klebsiella pneumoniae and
More informationINTRODUCTION. Original Article
Chattagram Maa-O-Shishu Hospital Medical College Journal Original Article Comparison Between Phenotypic Confirmatory Test & Double Disc Synergy Test in Detection of Extended Spectrum β-lactamases Producers
More informationDetection and characterization of extended spectrum β-lactamase producing Escherichia coli from poultry of eastern India
Detection and characterization of extended spectrum β-lactamase producing Escherichia coli from poultry of eastern India Dr. Samiran Bandyopadhyay Scientist Indian Veterinary Research Institute Eastern
More informationJAC A nosocomial outbreak of Pseudomonas aeruginosa isolates expressing the extended-spectrum β-lactamase GES-2 in South Africa
Journal of Antimicrobial Chemotherapy (2002) 49, 561 565 JAC A nosocomial outbreak of Pseudomonas aeruginosa isolates expressing the extended-spectrum β-lactamase GES-2 in South Africa Laurent Poirel a,
More informationESBLs and KPCs: Impact of Revised CLSI Breakpoints on testing and Reporting Algorithms
ESBLs and KPCs: Impact of Revised CLSI Breakpoints on testing and Reporting Algorithms Stephen G. Jenkins, Ph.D. Director, Clinical Microbiology Laboratories New York/Presbyterian Hospital Weill Cornell
More informationReceived 23 December 2010/Returned for modification 11 January 2011/Accepted 7 February 2011
JOURNAL OF CLINICAL MICROBIOLOGY, Apr. 2011, p. 1608 1613 Vol. 49, No. 4 0095-1137/11/$12.00 doi:10.1128/jcm.02607-10 Copyright 2011, American Society for Microbiology. All Rights Reserved. Evaluation
More informationCombatting AMR: diagnostics
Combatting AMR: diagnostics Professor Neil Woodford Antimicrobial Resistance & Healthcare Associated Infections (AMRHAI) Reference Unit Crown copyright Gonorrhoea: a paradigm for better diagnostics International
More informationOriginal article DOI: Journal of International Medicine and Dentistry 2016; 3(1): 34-41
Original article DOI: http://dx.doi.org/10.18320/jimd/201603.0134 JOURNAL OF INTERNATIONAL MEDICINE AND DENTISTRY To search..to know...to share p-issn: 2454-8847 e-issn: 2350-045X Comparative analysis
More informationANTIMICROBIAL SUSCEPTIBILITY TESTING: ADVANCED
ANTIMICROBIAL SUSCEPTIBILITY TESTING: ADVANCED Romney Humphries, Ph.D., DABMM Section Chief, Clinical Microbiology University of California Los Angeles Lost Angeles, CA Susan E. Sharp, Ph.D., DABMM, FAAM
More informationOccurrence and Detection of AmpC β-lactamases among Enterobacteriaceae in a Tertiary Care Centre in Trivandrum, India
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 7 Number 08 (2018) Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/10.20546/ijcmas.2018.708.023
More informationReceived 17 September 2008/Returned for modification 29 October 2008/Accepted 18 November 2008
JOURNAL OF CLINICAL MICROBIOLOGY, Feb. 2009, p. 294 299 Vol. 47, No. 2 0095-1137/09/$08.00 0 doi:10.1128/jcm.01797-08 Copyright 2009, American Society for Microbiology. All Rights Reserved. Identification
More informationAbstract. Introduction
ORIGINAL ARTICLE 10.1111/j.1469-0691.2009.02893.x Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin clavulanate and piperacillin tazobactam with extended-spectrum
More informationDepartment of Microbiology, University College of Medical Sciences & Guru Tegh Bahadur Hospital & *
Indian J Med Res 122, October 2005, pp 330-337 Phenotypic characteristics of clinical isolates of Klebsiella pneumoniae & evaluation of available phenotypic techniques for detection of extended spectrum
More informationFrequency and diversity of Class A extended-spectrum b-lactamases in hospitals of the Auvergne, France: a 2 year prospective study
Journal of Antimicrobial Chemotherapy (2004) 54, 634 639 DOI: 10.1093/jac/dkh395 Advance Access publication 28 July 2004 JAC Frequency and diversity of Class A extended-spectrum b-lactamases in hospitals
More informationRaymond G. Batchoun, Samer F. Swedan, and Abdullah M. Shurman. 1. Introduction
Hindawi Publishing Corporation International Journal of Microbiology Volume 2009, Article ID 513874, 8 pages doi:10.1155/2009/513874 Research Article ExtendedSpectrumβ-Lactamases among Gram-Negative Bacterial
More informationDifficult or Tricky Antibiotic Resistance Phenotypes to Recognize. Tan Thean Yen
Difficult or Tricky Antibiotic Resistance Phenotypes to Recognize Tan Thean Yen Contents Gram-positive Staphylococcus aureus with penicillinase production Vancomycin resistant Enterococci (VRE) Staphylococcus
More informationValidation of the Automated Reading and Incubation System with Sensititre Plates for Antimicrobial Susceptibility Testing
JOURNAL OF CLINICAL MICROBIOLOGY, May 2003, p. 1951 1956 Vol. 41, No. 5 0095-1137/03/$08.00 0 DOI: 10.1128/JCM.41.5.1951 1956.2003 Copyright 2003, American Society for Microbiology. All Rights Reserved.
More informationExtended spectrum AmpC and metallo-beta-lactamases in Serratia and Citrobacter spp. in a disc approximation assay
Original Article Extended spectrum AmpC and metallo-beta-lactamases in Serratia and Citrobacter spp. in a disc approximation assay Meher Rizvi, Nazish Fatima, Mohd. Rashid, Indu Shukla, Abida Malik, Aayesha
More informationEvaluation of a 12 Disc Test for Phenotypic Detection of β- lactamases Resistance in Gram Negative Bacilli
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 5 Number 6 (2016) pp. 105-114 Journal homepage: http://www.ijcmas.com Original Research Article http://dx.doi.org/10.20546/ijcmas.2016.506.013
More informationComparison of different methods of determining b-lactam susceptibility in clinical strains of Pseudomonas aeruginosa
Journal of Medical Microbiology (2009), 58, 625 629 DOI 10.1099/jmm.0.005587-0 Comparison of different methods of determining b-lactam susceptibility in clinical strains of Pseudomonas aeruginosa Eva Torres,
More informationFaecal prevalence of extended-spectrum ß-lactamase (ESBL)- producing coliforms in a geriatric population and among haematology patients
Malaysian J Pathol 2005; 27(2) : 75 81 FAECAL ESBL-PRODUCING COLIFORMS Faecal prevalence of extended-spectrum ß-lactamase (ESBL)- producing coliforms in a geriatric population and among haematology patients
More informationA Verification Study for Implementing the Revised CLSI Breakpoints. Summary. Breakpoint Differences Cephalosporin Breakpoints for Enterobacteriaceae
A Verification Study for Implementing the Revised CLSI Breakpoints Jean B. Patel, PhD, D(ABMM) Deputy Director, Office of Antimicrobial Resistance National Center for Emerging and Zoonotic Infectious Disease
More informationA Verification Study for Implementing the Revised CLSI Breakpoints. Summary. Glossary CDC 1
A Verification Study for Implementing the Revised CLSI Breakpoints Jean B. Patel, PhD, D(ABMM) Deputy Director, Office of Antimicrobial Resistance National Center for Emerging and Zoonotic Infectious Disease
More informationThe Prevalence of TEM-1 gene causing resistance to beta-lactam antibiotics in Klebsiella pneumoniae isolates from clinical samples and plasmid curing
Available online at www.ijmrhs.com ISSN No: 2319-5886 International Journal of Medical Research & Health Sciences, 2016, 5, 11:557-561 The Prevalence of TEM-1 gene causing resistance to beta-lactam antibiotics
More informationEmergence and persistence of integron structures harbouring VIM genes in the Children s Memorial Health Institute, Warsaw, Poland,
Journal of Antimicrobial Chemotherapy (2009) 63, 269 273 doi:10.1093/jac/dkn512 Advance Access publication 18 December 2008 Emergence and persistence of integron structures harbouring VIM genes in the
More informationAbstract. Introduction
ORIGINAL ARTICLE BACTERIOLOGY A sensitive and specific phenotypic assay for detection of metallo-blactamases and KPC in Klebsiella pneumoniae with the use of meropenem disks supplemented with aminophenylboronic
More informationKey words: ESBLs; Ceftriaxone; Escherichia coli; MICs; Bacteremia
JCM Accepts, published online ahead of print on 16 April 2014 J. Clin. Microbiol. doi:10.1128/jcm.00716-14 Copyright 2014, American Society for Microbiology. All Rights Reserved. 1 1 2 Title: Determining
More informationORIGINAL ARTICLE /j x. Hospital Universitario Virgen Macarena, Seville, Spain
ORIGINAL ARTICLE 10.1111/j.1469-0691.2005.01194.x Long-term study of the frequency of Escherichia coli and Klebsiella pneumoniae isolates producing extended-spectrum b-lactamases L. Romero 1,L.López 1,
More informationGenetic support of Extended- Spectrum ß-Lactamases
Genetic support of Extended- Spectrum ß-Lactamases Laurent Poirel Dept of Microbiology (Pr Nordmann) Bicêtre Hospital. South-Paris Medical School. France ESCMID Conference on ESBL 29-31 May 2006 TEM-like
More informationCarbapenem-resistant Enterobacteriaceae (CRE): Surveillance and Response. David Selvage, MHS, PA-C New Mexico Department of Health March 15, 2016
Carbapenem-resistant Enterobacteriaceae (CRE): Surveillance and Response David Selvage, MHS, PA-C New Mexico Department of Health March 15, 2016 What are Carbapenem-resistant Enterobacteriaceae (CRE)?
More informationEvaluation of the Osiris Expert System for Identification of -Lactam Phenotypes in Isolates of Pseudomonas aeruginosa
JOURNAL OF CLINICAL MICROBIOLOGY, Aug. 2003, p. 3712 3718 Vol. 41, No. 8 0095-1137/03/$08.00 0 DOI: 10.1128/JCM.41.8.3712 3718.2003 Copyright 2003, American Society for Microbiology. All Rights Reserved.
More informationSusceptibility Tests
JOURNAL OF CLINICAL MICROBIOLOGY, Aug. 1982, p. 213-217 Vol. 16, No. 2 0095-1137/82/080213-05$02.00/0 In Vitro Studies with Cefotaxime: Disk Diffusion Susceptibility Tests SMITH SHADOMY* AND EDWARD L.
More informationMolecular susceptibility testing
Molecular susceptibility testing Dr Andrew Ginn Supervising Scientist Antimicrobial Resistance Reference Laboratory ICPMR, Westmead Hospital Resistance genes Gram negatives Transmissible; e.g. ESBLs, MBLs,
More informationOngoing epidemic of bla VIM-1 -positive Klebsiella pneumoniae in Athens, Greece: a prospective survey
Journal of Antimicrobial Chemotherapy (2008) 61, 59 63 doi:10.1093/jac/dkm443 Advance Access publication 13 November 2007 Ongoing epidemic of bla VIM-1 -positive Klebsiella pneumoniae in Athens, Greece:
More informationOccurrence of TEM & SHV gene in extended spectrum b-lactamases (ESBLs) producing Klebsiella sp. isolated from a tertiary care hospital
Indian J Med Res 125, February 2007, pp 173-178 Occurrence of TEM & SHV gene in extended spectrum b-lactamases (ESBLs) producing Klebsiella sp. isolated from a tertiary care hospital Prabha Lal, Arti Kapil,
More informationPrevalence of AMPC Beta Lactamases among Gram Negative Bacterial Isolates in a Tertiary Care Hospital
ISSN: 2319-7706 Volume 4 Number 9 (2015) pp. 219-227 http://www.ijcmas.com Original Research Article Prevalence of AMPC Beta Lactamases among Gram Negative Bacterial Isolates in a Tertiary Care Hospital
More informationBD BBL CHROMagar CPE
INSTRUCTIONS FOR USE READY-TO-USE PLATED MEDIA BD BBL CHROMagar CPE PA- 257681.02 Rev. January 2017 INTENDED USE BD BBL CHROMagar CPE is a selective chromogenic screening medium for the detection of carbapenemase
More informationJAC Aspartic acid for asparagine substitution at position 276 reduces susceptibility to mechanism-based inhibitors in SHV-1 and SHV-5 -lactamases
Journal of Antimicrobial Chemotherapy (1999) 43, 23 29 JAC Aspartic acid for asparagine substitution at position 276 reduces susceptibility to mechanism-based inhibitors in SHV-1 and SHV-5 -lactamases
More informationOXA-type beta-lactamases among extended-spectrum cephalosporin-resistant Pseudomonas aeruginosa isolates in a university hospital in southern Taiwan
OXA-type J Microbiol ESBLs Immunol in P. Infect aeruginosa 2006;39:130-134 OXA-type beta-lactamases among extended-spectrum cephalosporin-resistant Pseudomonas aeruginosa isolates in a university hospital
More informationTitle: Detection of carbapenemases in Enterobacteriaceae by a commercial multiplex PCR
JCM Accepts, published online ahead of print on 11 July 2012 J. Clin. Microbiol. doi:10.1128/jcm.00991-12 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 2 3 4 5 6 7 8 9 10 11
More informationThe ARLN: CRE and CRPA Testing & Troubleshooting Lab Results 5/3/2017
The ARLN: CRE and CRPA Testing & Troubleshooting Lab Results 5/3/2017 After the program, send questions to ARLN@cdc.gov. Speakers Maria Karlsson, PhD, Clinical and Environmental Microbiology Branch, Division
More informationRapid Diagnostic Tests for Antimicrobial Resistance: Comparability of Results and Interpretation of Data
Rapid Diagnostic Tests for Antimicrobial Resistance: Comparability of Results and Interpretation of Data Christopher Teale, Animal and Plant Health Agency, UK. 12 th OIE One-Day Seminar, in association
More informationReal-Time PCR and Melting Curve Analysis for Reliable and Rapid Detection of SHV Extended-Spectrum -Lactamases
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, June 2001, p. 1730 1736 Vol. 45, No. 6 0066-4804/01/$04.00 0 DOI: 10.1128/AAC.45.6.1730 1736.2001 Copyright 2001, American Society for Microbiology. All Rights Reserved.
More informationReal-Time PCR and Melting Curve Analysis for Reliable and Rapid Detection of SHV Extended-Spectrum -Lactamases
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, June 2001, p. 1730 1736 Vol. 45, No. 6 0066-4804/01/$04.00 0 DOI: 10.1128/AAC.45.6.1730 1736.2001 Copyright 2001, American Society for Microbiology. All Rights Reserved.
More informationCarbapenem Resistance in Klebsiella pneumoniae Not Detected by Automated Susceptibility Testing
Carbapenem Resistance in Klebsiella pneumoniae Not Detected by Automated Susceptibility Testing Fred C. Tenover,* Rajinder K. Kalsi, Portia P. Williams, Roberta B. Carey,* Sheila Stocker,* David Lonsway,*
More informationCharacteristics and Molecular Epidemiology of Cefotaxime Resistant Enterobacteriaceae Isolated from Healthy College Students
桐蔭論叢 第 34 号 2016 年 6 月 医用工学部研究論文 Characteristics and Molecular Epidemiology of Cefotaxime Resistant Enterobacteriaceae Isolated from Healthy College Students 桐蔭横浜大学医用工学部生命医工学科 (2016 年 3 月 28 日受理 ) 1. Introduction
More informationAntibiotic Susceptibility Testing (ABST/AST)
Antibiotic Susceptibility Testing (ABST/AST) Goal Offer guidance to physicians in selecting effective antibacterial therapy for a pathogen in a specific body site. Performed on bacteria isolated from clinical
More informationInt.J.Curr.Microbiol.App.Sci (2016) 5(4):
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 5 Number 4 (2016) pp. 133-139 Journal homepage: http://www.ijcmas.com Original Research Article http://dx.doi.org/10.20546/ijcmas.2016.504.018
More informationCharacterization of Class 1 Integron Gene Cassettes among Clinical Bacteria Isolated from One Large Hospital in Northern China *
Biomed Environ Sci, 2013; 26(12): 1003-1007 1003 Letter to the Editor Characterization of Class 1 Integron Gene Cassettes among Clinical Bacteria Isolated from One Large Hospital in Northern China * CHEN
More informationantibiotic resistance blakpc
Techne qpcr test antibiotic resistance blakpc Carbepenem-hydrolyzing beta-lactamase KPC-1 (blakpc) gene 150 tests For general laboratory and research use only 1 Introduction to antibiotic resistance blakpc
More informationCuring antibiotic resistance in vivo. Muhammad Kamruzzaman
Curing antibiotic resistance in vivo Muhammad Kamruzzaman Occurrence of resistance -Some bacteria are naturally resistant to certain antibiotics -Gene mutation -Horizontal transfer of antibiotic resistance
More informationCurriculum Vitae. Abbas Maleki, Ph.D. Clinical Microbiology Research Center, Ilam University of Medical Sciences, Ilam, Iran
Curriculum Vitae Abbas Maleki, Ph.D Clinical Microbiology Research Center, Ilam University of Medical Sciences, Ilam, Iran E-mail: abbasmaleki_ilam@yahoo.com maleki-a@medilam.ac.ir Tel: +989187419401 Personal
More informationRole of inducers in detection of bla PDC resistance in Pseudomonas aeruginosa
Indian J Med Res 145, May 2017, pp 659-664 DOI: 10.4103/ijmr.IJMR_628_15 Quick Response Code: Role of inducers in detection of bla PDC -mediated oxyiminocephalosporin resistance in Pseudomonas aeruginosa
More informationSupplementary Information for
Supplementary Information for Direct, rapid antimicrobial susceptibility test from positive blood cultures based on microscopic imaging analysis J. Choi 1, H. Y. Jeong 2,3, G. Y. Lee 2,4, S. Han 1, S.
More informationVariable susceptibility to piperacillin/tazobactam amongst Klebsiella spp. with extended-spectrum β-lactamases
Journal of Antimicrobial Chemotherapy (2003) 51, 605 612 DOI: 10.1093/jac/dkg114 Advance Access publication 28 January 2003 Variable susceptibility to piperacillin/tazobactam amongst Klebsiella spp. with
More informationTransferable Cefoxitin Resistance in Enterobacteria from Greek Hospitals and Characterization of a Plasmid-Mediated Group 1 -Lactamase (LAT-2)
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, July 1996, p. 1736 1740 Vol. 40, No. 7 0066-4804/96/$04.00 0 Copyright 1996, American Society for Microbiology Transferable Cefoxitin Resistance in Enterobacteria
More informationLauren A. Darling1#, Ann M. Evans1, Kathleen A. Stellrecht1,2, Seela M. Nattanmai1,
JCM Accepted Manuscript Posted Online 20 September 2017 J. Clin. Microbiol. doi:10.1128/jcm.01185-17 Copyright 2017 American Society for Microbiology. All Rights Reserved. 1 JCM Letter to the Editor Submission
More informationAntimicrobial Susceptibility Testing Disk Diffusion
Antimicrobial Susceptibility Testing Disk Diffusion Babak Valizadeh,DCLS Babak_Valizadeh@hotmail.com 1390 / 09 / 10 2011.12.01 1 2 3 CLSI - M02-A10 / 2009 4 CLSI M100-S21 / 2011 Antimicrobial Susceptibility
More informationThe Laboratory Diagnosis of Enterobacteriaceae that produce Carbapenemases. and Johann DD Pitout 1-3
JCM Accepts, published online ahead of print on 19 September 2012 J. Clin. Microbiol. doi:10.1128/jcm.02117-12 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 The Laboratory Diagnosis
More informationPERANAN MIKROBIOLOGI DALAM DIAGNOSIS PENYAKIT INFEKSI. dr. Agus Eka Darwinata, Ph.D.
PERANAN MIKROBIOLOGI DALAM DIAGNOSIS PENYAKIT INFEKSI dr. Agus Eka Darwinata, Ph.D. CLINICAL MICROBIOLOGY Clinical microbiology is the discipline of detection, characterization, and quantification of
More informationExtended-Spectrum β-lactamases Producing Escherichia coli Strains Monitored Over 4 Years in The University Hospital in Košice, Slovakia
Current Research in Microbiology Original Research Paper Extended-Spectrum β-lactamases Producing Escherichia coli Strains Monitored Over 4 Years in The University Hospital in Košice, Slovakia 1 Viera
More informationIOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 16, Issue 10 Ver. VII (Oct. 2017), PP 76-81 www.iosrjournals.org Molecular Characterization of TEM, SHV
More informationDetection of Plasmid-Mediated AmpC -Lactamase Genes in Clinical Isolates by Using Multiplex PCR
JOURNAL OF CLINICAL MICROBIOLOGY, June 2002, p. 2153 2162 Vol. 40, No. 6 0095-1137/02/$04.00 0 DOI: 10.1128/JCM.40.6.2153 2162.2002 Copyright 2002, American Society for Microbiology. All Rights Reserved.
More informationReceived 24 June 2008/Returned for modification 12 August 2008/Accepted 14 September 2008
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Dec. 2008, p. 4268 4273 Vol. 52, No. 12 0066-4804/08/$08.00 0 doi:10.1128/aac.00830-08 Copyright 2008, American Society for Microbiology. All Rights Reserved. High
More informationgenerated by the usage of antimicrobial drugs is absent. She is the author of 14 publications in international journals.
Fernando Baquero Doctor in Medicine, Ramón y Cajal Research Professor in Bacterial Evolution at the Biomedical Research Foundation and Department of Microbiology of the Ramón y Cajal Universty Hospital.
More informationAmpicillin-Sulbactam and Amoxicillin-Clavulanate Susceptibility Testing of Escherichia coli Isolates with Different -Lactam Resistance Phenotypes
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 1999, p. 862 867 Vol. 43, No. 4 0066-4804/99/$04.00 0 Copyright 1999, American Society for Microbiology. All Rights Reserved. Ampicillin-Sulbactam and Amoxicillin-Clavulanate
More informationEXTENDED SPECTRUM BETA (Β) LACTAMASES IN CLINICAL ISOLATES OF GRAM-NEGATIVE BACILLI IN AJMAN, UNITED ARAB EMIRATES
GMJ ORIGINAL ARTICLE EXTENDED SPECTRUM BETA (Β) LACTAMASES IN CLINICAL ISOLATES OF GRAM-NEGATIVE BACILLI IN AJMAN, UNITED ARAB EMIRATES Ekta Chourasia, Krishna Pratap Singh, Sudheer Keshav Kher ABSTRACT
More informationAmpicillin-Sulbactam and Amoxicillin-Clavulanate Susceptibility Testing of Escherichia coli Isolates with Different -Lactam Resistance Phenotypes
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 1999, p. 862 867 Vol. 43, No. 4 0066-4804/99/$04.00 0 Copyright 1999, American Society for Microbiology. All Rights Reserved. Ampicillin-Sulbactam and Amoxicillin-Clavulanate
More informationAntimicrobial Agents and Chemotherapy New Data Letter
AAC Accepted Manuscript Posted Online 15 August 2016 Antimicrob. Agents Chemother. doi:10.1128/aac.01519-16 Copyright 2016, American Society for Microbiology. All Rights Reserved. 1 Antimicrobial Agents
More informationEmerging Resistance in Gram- Negative Bacteria CLSI Recommendations. James H. Jorgensen, PhD
Emerging Resistance in Gram- Negative Bacteria CLSI Recommendations James H. Jorgensen, PhD Most Important Emerging or Evolving Resistance in GNs Newer ESBLs Plasmid-mediated mediated AmpCs KPCs, VIM,
More informationEzy MIC Strip FEATURES AND ADVANTAGES
Imipenem with & without EDTA Ezy MIC Strips (IPM+EDTA/IPM) (Imipenem + EDTA: 1-64 mcg/ml) (Imipenem : 4-256 mcg/ml) Antimicrobial Susceptibility Testing For In Vitro Diagnostic use EM078 Not for Medicinal
More informationThe occurrence of AmpC β-lactamase and ESBL producing Gram-negative bacteria by a simple..
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 14, Issue 12 Ver. I (Dec. 2015), PP 19-24 www.iosrjournals.org The occurrence of AmpC β-lactamase and
More informationNew Efforts in Combating Antibiotic Resistance The Antibiotic Resistance Laboratory Network
New Efforts in Combating Antibiotic Resistance The Antibiotic Resistance Laboratory Network Paula Snippes Vagnone MT(ASCP) July 11, 2017 MN Laboratory System Webinar Series Objectives Describe the ARLN,
More informationInvestigational New Drug - Groundwork for in vitro antimicrobial susceptibility testing
Investigational New Drug - Groundwork for in vitro antimicrobial susceptibility testing Erika Matuschek, Ph D Lead Scientist/Operational Manager EUCAST Development Laboratory (EDL) Växjö, Sweden ASM/ESCMID
More informationORIGINAL ARTICLE /j x
ORIGINAL ARTICLE 10.1111/j.1469-0691.2006.01645.x Development and clinical validation of a molecular diagnostic assay to detect CTX-M-type b-lactamases in Enterobacteriaceae J. D. D. Pitout 1,2,3, N. Hamilton
More informationPREVALENCE OF EXTENDED SPECTRUM BETA-LACTAMASE PRODUCING PROTEUS IN RAW MILK, MILK PRODUCTS AND UTI PATIENTS
PREVALENCE OF EXTENDED SPECTRUM BETA-LACTAMASE PRODUCING PROTEUS IN RAW MILK, MILK PRODUCTS AND UTI PATIENTS *Syed Waseem Sajad Department of Microbiology, Singhania University, Jhunjhunu, Rajasthan India
More informationProtocols for Laboratory Verification of Performance of the BioFire FilmArray Blood Culture Identification (BCID) Panel
Protocols for Laboratory Verification of Performance of the BioFire FilmArray Blood Culture Identification (BCID) Panel Laboratory Protocols for Use with Microbiologics Helix Elite Molecular Standards
More information